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Stem cells hold great promise for treating and 
potentially curing many diseases for which no therapy 
currently exists. However, several misconceptions of 
stem cells exist among the general public and, to an 
extent, among the medical fraternity. Most of these misconceptions 
can be resolved by understanding the basic biology of stem cells, 
which would be critical to address prior to arguing the associated 
ethical and legal implications that arise from the use of stem cells for 
therapeutic purposes.
A stem cell has the unique ability to both replicate and develop 
into specialised tissues with specific functions. Different forms of 
stem cells exist, each with varying capacity or potency. The potency 
refers to the extent to which the stem cell is able to replicate and 
differentiate into multiple tissues. When the female egg cell is 
fertilised by the male sperm, a totipotent stem cell is created, from 
which a complete human body and placenta develops. On the fourth 
day of development, the embryo forms an outer layer of cells and 
an inner cell mass. The outer layer develops into the placenta, while 
the inner cell mass develops into the human body/fetus. Embryonic 
stem cells (ESCs) are derived from the inner cell mass and are referred 
to as pluripotent stem cells. Somatic stem cells (often referred to as 
adult stem cells) are stem cells that reside in tissues and organs of 
the developed human body for the purpose of providing a renewal 
and regenerative capacity. This capacity is generally limited to the 
tissue-group within which these stem cells reside. These stem cells 
are referred to as multipotent stem cells. Best known examples of 
multipotent stem cells are haematopoietic stem cells (HSCs), which 
give rise to all of the cellular components of blood; mesenchymal 
stem cells (MSCs), which are able to develop into bone, cartilage, 
muscle and fat; and neural stem cells (NSCs), which develop into cells 
of the nervous system. 
From a therapeutic point of view, HSCs are the only form of globally 
accepted stem cell therapy. These cells are used for the treatment 
of blood and blood-related disorders, and are common practice in 
nearly 80 countries. This is a well-described and rational approach 
where ‘blood-making’ stem cells are used specifically in the context 
of replacing defective blood cells. Of the more than 60 000 HSC 
transplants that take place globally per annum, approximately 90% 
are for treating blood cancers (leukaemia, lymphoma and myeloma), 
while the remaining indications include solid tumours and non-
malignant conditions such as thalassaemia, sickle cell disease and 
immune disorders. In each of these cases, the HSCs are used to 
replenish blood cells that are depleted in a chemotherapy regimen 
received prior to the transplantation. 
Over the past decade, the potential benefits of MSCs for treatment 
purposes have gained tremendous interest. There are several reasons 
for this, including the fact that these cells: 
• Can be procured fairly easily (particularly from fat)
• Have the unique ability to migrate to the site of injury once injected
• Do not require genetic matching when obtained from a donor (as 
is the case with HSCs). 
By investigating the global clinical trial landscape of MSCs, it was 
possible to identify over 100 different indications that have been or are 
currently being treated with MSCs (manuscript in preparation). These 
include diseases such as arthritis, heart attacks, multiple sclerosis, 
diabetes and spinal cord injuries. However, although widespread 
interest in this area of research exists, only one MSC product has 
successfully achieved market approval from regulatory authorities – 
remestencel-L (Prochymal®), which was approved in Canada and New 
Zealand for the treatment of graft v. host disease, a complication of 
HSC transplantation.[1] 
The stem cell controversies of the past two decades originated from 
the use of ESCs for medical research. Given that a fertilised embryo is 
destroyed in order derive these cells, albeit in the laboratory setting 
with donated embryos, such research was deemed unacceptable 
by many and understandably has resulted in a quagmire of ethical 
debates.[2] More recently, however, the use of unproven stem cell 
therapies and the subsequent emergence of a ‘stem cell tourism’ 
industry have provided a concerning source of controversy.[3] In such 
cases, vulnerable patients are enticed to travel abroad to dubious 
stem cell clinics and are subjected to unproven stem cell therapies at 
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their own expense. Given the unique properties of MSCs and the ease 
with which they can be prepared from fat tissue, they have become 
the most attractive product on offer at a large number of suspicious 
stem cell clinics around the world. The most concerning aspect of 
this is the extensive list of diseases that these clinics claim to treat. 
Although over 100 indications are being treated in the clinical trial 
setting, none have been able to demonstrate sufficient benefit (with 
the exception of the previously mentioned Prochymal® preparation). 
In December 2014, the Food and Drug Administration (FDA) – 
the American regulatory authority – released two draft guidance 
documents, describing their view on the preparation of MSCs from fat 
and their use in patients. In essence, these draft guidelines state that 
MSCs are to be regarded as biological drugs in future, meaning that the 
provider and/or manufacturer will have to prove benefit in the clinical 
trial setting before it will be reviewed and considered for marketing 
approval by the FDA. Once this becomes official, no clinic in the USA 
will be able to offer unproven MSC products legally. Since there is no 
approved MSC therapy in the US market, any clinic preparing MSCs 
for treatment purposes will stand the risk of having to engage legally 
with the FDA, for which the outcome will in all likelihood be in favour 
of the latter. It is anticipated that regulatory authorities in other major 
markets will follow suit, particularly the European Union. 
Stem cell therapy as biological medicine
In South Africa (SA) MSC therapy is similarly categorised as a biological 
medicine in terms of the Medicine Control Council’s (MCC). Guidelines for 
the Registration of Medicines where the active ingredient or key excipients 
have been derived from living organisms or tissues, or manufactured 
using a biological process.[4] Biological medicines are therefore largely 
differentiated from other medicines through the methods used to 
manufacture them and include ‘medicines prepared from substrates 
such as: (1) microbial cultures (fermentation); (2) plant or animal cell 
cultures (including those resulting from recombinant DNA or hybridoma 
techniques); (3) extraction from biological tissues; and (4) propagation of 
live agents in embryos or animals.’[5] Considering its production methods 
stem cell therapy qualifies as biological medicine and falls within the ambit 
of the Medicines and Related Substances Control Act (MRSCA).[6]     
The classification of stem cell therapy as biological medicine with 
regard to autologous stem cell therapy, where a patient’s own stem 
cells are administered back to the same patient after having been 
processed, cultured, mixed with other therapeutic substances, stored 
or even cryopreserved, was challenged in the USA in the Regenexx-
case.[7] In this case the FDA claimed that the autologous stem cell 
based substance produced using the Regenexx procedure qualifies 
as a ‘biological product’ that falls within the regulatory ambit of the 
FDA and subsequently ordered its developers, Regenerative Sciences, 
to stop offering their unapproved biological drug product. However, 
foreign to SA regulations, the FDA regulations mandate the FDA to 
only regulate so-called ‘one-on-many’ public health risks as opposed 
to ‘one-on-one’ doctor-patient medical care risks. The developers 
of Regenexx argued that their product, based on its ‘one-on-one’ 
doctor-patient medical care risk, did not fall under the regulation 
of the FDA and accordingly did not require any approval from the 
FDA. The important fact is that the court found that ‘the biological 
characteristics of the cells changed during the process’ causing the 
cells to be more than ‘minimally manipulated’ resulting in a biological 
medicinal product. In SA, autologous stem cell products similar to 
Regenexx also qualify as biological medicine, as described above and 
will be regulated by the MRSCA.[5] 
Registration of biological medicine 
The MRSCA prohibits the sale of any unregistered medicine which is 
subject to registration.[8] An official notice issued in terms of the MRSCA 
by the MCC specifically subjects all medicines that are biological 
medicine to registration with the MCC.[9] Only when the Registrar of 
Medicines is satisfied that medicine is safe, efficacious, of good quality 
and suitable for the purpose for which it is intended, complies with 
the prescribed requirements and that registration thereof is in the 
public interest will he or she approve an application for registration 
and issue the applicant with a certificate of registration, which after 
the registered medicine can be legally sold.[10]
Biological medicine will also be evaluated for safety, quality and 
efficacy by the Biological Medicines Committee prior to registration, 
in addition to the standard MCC committees.[11] In this regard the 
MCC will consider both national and international guidelines such 
as the International Conference on Harmonisation (ICH) of Technical 
Requirements for Registration of Pharmaceuticals for Human Use, 
which focuses on global harmonisation of safety, efficacy and quality 
standards resulting from Good Manufacturing Practices and properly 
designed and conducted clinical trials.[12]
Although selling unregistered medicine is an offence punishable 
with a fine and/or imprisonment not exceeding 10 years, prosecutions 
and convictions are extremely rare.[13] 
Consequences of unproven or fraudulent 
stem cell therapy
It has been recorded that money spent on stem cell tourism, including 
clinically unproven treatments, averages around R122 500, and that 
some stem cell tourists even received stem cells from animals such as 
sheep or rabbits.[14]   
From 2002 to 2006 Biomark International, a biotechnology company in 
the USA, defrauded individuals suffering from amyotrophic lateral sclerosis 
(Lou Gehrig’s disease), Parkinson’s disease, muscular dystrophy, multiple 
sclerosis and other incurable diseases by making false representations 
‘...that science had proven the therapeutic power of stem cells and that 
Biomark was simply making it available to the world.’[15] Under these 
pretences every patient was injected with the same type and quantity of 
stem cells, regardless of the disease the patient was suffering from and 
charged between US$10 000 and US$32 000, if not negotiated otherwise. 
In 2006 Laura Brown and Stephen Mark van Rooyen, directors of Biomark, 
were criminally indicted. During their hearing the court found that 
Biomark’s website and advertisements made numerous false, misleading 
and inaccurate statements and that the proffered information had no 
scientific credibility. It further found that the stem cell treatments were 
illegally administered without a biologics product licence[16] and that 
licensing was very unlikely as pre-clinical trials in this regard only involved 
non-humans. None of the patients undergoing these treatments were 
cured and many even died during treatment. 
Undesirable practices
Joint efforts of stem cell researchers, clinicians, ethicists and regulatory 
officials from 13 countries culminated in the International Society for 
Stem Cell Research’s (ISSCR) Guidelines for the Clinical Translation 
of Stem Cells.[17] These guidelines acknowledge the worrisome 
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cases where unproven stem cell therapies are marketed, resulting 
in stem cell tourism to countries with insufficient local regulation 
and oversight of host clinics. It also condemns the administration of 
unproven stem cell therapy or direct derivatives to patients outside of 
a clinical trial, especially when charged for such services. It states that 
countries hosting illegal therapies have a responsibility to prevent 
patient exploitation and urges them to close fraudulent clinics and 
take disciplinary action against involved clinics.
Locally, authorised institutions[18] may acquire, use and supply 
any blood products, including stem cells, for prescribed medical 
purposes, the advancement of health and therapeutic services 
and the production of therapeutic, diagnostic or prophylactic 
substances.[19] These activities are largely controlled by the Minister 
of Health as only he has the authority to authorise cell removal and 
impose conditions.[20] This process may significantly frustrate or delay 
translational stem cell research. Regulations, issued in terms of the 
National Health Act (NHA) which only requires informed consent 
from the stem cell donor when acquiring cells, contradicts this 
prescription, leaving legal uncertainty in its wake.[21]
The MRSCA requires that the Director-General of Health must 
be informed of the therapeutic efficacy and effect of any medicine 
as soon as practically possible after registration with the MCC, 
including the purpose, circumstances and manner in which such 
medicine should be used.[22] Any advertisements subsequent to such 
registration, making any claims regarding the therapeutic effects and 
efficacy of the medicine or use thereof for any purposes contrary 
to the reported effects, efficacy and purpose of use is prohibited as 
being false or misleading.[23]
All transactions or agreements concluded between healthcare 
providers and patients for the supply of healthcare goods, including 
biological medicine, or services in exchange for consideration, 
including the marketing of stem cell therapies, falls within the ambit 
of the Consumer Protection Act (CPA).[24] 
The CPA also prohibits false or misleading marketing which 
includes deceptions of the nature, properties, advantages or uses 
of goods or services, the conditions under which and the prices 
at which goods or services can be supplied or any other material 
aspect.[25] Patients may therefore not be enticed into stem cell therapy 
with scientifically unproven promises or false statements relating 
to the exact nature and possible effects of such therapy. Patients 
suffering from debilitating diseases are often physically and mentally 
handicapped as a result and unable to substantially protect their own 
interests. Should physical force, coercion, undue influence, pressure, 
duress, harassment or unfair tactics be used against these patients 
when marketing, supplying or negotiating the supply of any stem 
cell therapy, such conduct will amount to being unconscionable in 
terms of the CPA.[26] Practices where suppliers of stem cell therapy 
knowingly take advantage of illiterate, ignorant patients who are 
unable to understand the language of the agreement are prohibited 
by the CPA. Failing to correct patients’ apparent misapprehension 
of proposed stem cell therapy, using exaggeration, innuendo or 
ambiguity as to material facts or failing to disclose material facts 
relating to stem cell therapy will also amount to a false, misleading 
or deceptive representation.[27] Any agreement between patients 
and suppliers of stem cell therapies which subjects patients to any 
of the aforementioned fraudulent conduct, contravenes any of the 
provisions of the CPA or constitutes an assumption of risk or liability 
by the patient for losses suffered resulting from the gross negligence 
of suppliers or any persons acting for or on behalf of suppliers is 
strictly prohibited.[28] The agreed price for the therapy as well as the 
manner in which the therapy will be administered must also be 
fair, reasonable, just and may not waive any liability of suppliers or 
rights of patients.[29] Liability resulting from stem cell therapy can 
accordingly not be escaped through contractual terms.
Any contravention of the aforementioned provisions, which may 
result in serious illness, disablement or even death of the patient, 
is considered to be serious enough that patients may deviate from 
the standard consumer complaint route and directly approach the 
court to restore money to the patient or compensate the patient for 
losses or expenses relating to harm suffered resulting from stem cell 
therapy transactions or agreements, including the patient’s legal costs 
relating to such court proceedings.[30] Although the CPA does not limit 
the heads of damages that may be claimed upon contravention of 
these prohibitions, it is arguable that the patient will also be entitled 
to claim for general damages. The court will, among others, consider 
the power imbalances between the parties which is influenced by 
the parties’ relationship to each other, their relative capacity to enter 
into contractual agreements, levels of education and sophistication, 
experience and bargaining position; whether the patient knew or 
ought reasonably to have known of the existence and extent of any 
unfair, unreasonable or unjust provisions contained in the agreement; 
the respective conduct of suppliers and patients; the amount for 
which, and circumstances under which the patient could have 
acquired identical or equivalent goods or services from a different 
supplier and whether the biological medicine was manufactured, 
processed or adapted to special orders of the patient.[31]     
The court can also require the supplier to cease any stem cell therapy 
or alter any practices to avoid a repetition of the supplier’s conduct in 
an effort to prevent further future harm to patients.[32] If the MCC is also 
of the opinion that it is not in the public interests that any medicine be 
made available to the public it may order the disposal of any undesirable 
medicine.[33] The premature translation of unproven stem cell therapy 
resulting in such court and disposal orders can destroy people’s trust in 
stem cell therapy and negatively impact on current translational research, 
future funding and development of this promising biological medicine.         
Patient safety
Although false and misleading advertising is punishable as a criminal 
offence in terms of the MRSCA,[34] these practices can also result in 
civil liability in terms of the implied warranty[35] and faultless liability 
regimen[36] provided for in the CPA. 
The CPA provides for the joint and individual liability of all persons 
involved in the chain supplying any unsafe, hazardous goods without 
adequate instructions or warnings pertaining to any hazard that can 
result from using such goods ‘...irrespective of whether the harm resulted 
from any negligence...’[37] on the suppliers’ part. A patient only needs 
to prove that the harm (death, injury, illness or pure economic loss) he 
wrongfully suffered resulted from unsafe or hazardous stem cell therapy, 
without adequate instructions or warnings pertaining to such hazards, to 
succeed with his claim against any person in the therapy’s supply chain.
Patients are entitled to assume that suppliers of stem cell therapies 
have the legal right to sell and administer biological medicine.[38] This 
presumption entails that a patient has the right to assume that any 
biological medicine offered as therapy has been registered with the MCC 
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subsequent to clinical studies providing evidence of product safety and 
established proof-of-principle for the desired therapeutic effect,[39] failing 
which, and upon suffering harm as a result of unproven, unregistered 
therapy, a patient can claim for damages as discussed above. 
Every patient has the right to information regarding proposed 
stem cell therapy in plain understandable language so that a person 
of average literacy skills and minimal experience as a consumer of 
biological medicine, could be expected to understand the content and 
significance of such information.[40] Considering the novelty of stem 
cell treatments almost everyone will be considered to have minimal 
experience with such therapy and with further regard to the complex 
and unpredictable nature thereof, healthcare practitioners will need 
to take extraordinary communication steps to ensure that patients 
adequately understand and consent to such therapies. Information 
relating to genetically modified ingredients or reconditioned goods, as 
may be the case with stem cell products, must be clearly displayed on the 
biological medicine’s packaging or prescribed notice.[41] This, as well as 
the extensive guidelines offered by the ISSCR[17] will further aid patients 
in exercising informed decisions regarding their treatment options.
 Patients can further expect goods or services to be safe, free of 
defects or hazard,[35,42] such as contamination, and of a quality that 
persons are generally entitled to expect from stem cell therapy.[43] 
Having regard to the novelty, unpredictability and unknown long-term 
results of stem cell therapy it is questionable what exactly persons are 
generally entitled to expect of it. What is clear is that unproven stem 
cell therapies, posing significant risks of personal injury, qualify as 
unsafe and hazardous in terms of the CPA, and patients are entitled to 
be protected from such dangers.     
Whenever the stipulations of any other act is in conflict with those 
contained in the CPA, the act offering the greater protection to the 
consumer, being the patient, will apply.[44]     
Medical innovation
Stem cell based medical innovation interventions are unproven stem 
cell based interventions outside the context of a formal clinical trial. 
In very limited cases the ISSCR guidelines allow clinicians to attempt 
medically innovative stem cell based interventions on seriously ill 
patients, albeit under heightened levels of caution and with informed 
consent clearly emphasising the experimental and preliminary nature 
of the clinical intervention.[45] A case in point is the stem cell therapy 
received by Gordon Howie, a Canadian ice hockey player, after suffering 
a stroke in October 2014.[46] However, due to the fact that patients do 
not receive these treatments for consideration, these transactions 
will locally not fall within the ambit of the CPA and patients will no 
longer enjoy the faultless liability the protection affords. However the 
principles of therapeutic research in SA include well-informed consent 
and the constitutional protection of research participants’ bodily 
and psychological integrity,[47] ethically reviewed research proposals 
to ensure safety monitoring and the management of any harm 
experienced by participants, including compensation for any research-
related injuries and providing for the long-term care and observation of 
participants of innovative therapy such as stem cell therapy.[48]  
Conclusion
In countries which are unregulated or poorly regulated, undesirable 
practices, inviting stem cell tourists and patient harm resulting from 
unproven stem cell therapy, would thrive as patients will increasingly 
move into areas that are medically untested. In SA the MRSCA, regulating 
the quality of biological medicine which enters the market through 
registration, and the CPA, providing patients with remedies when suffering 
harm or losses resulting from stem cell therapies, protects patients against 
undesirable practice and its inherent dangers to patient safety.  
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